Searched for
ALZHEIMER DRUG
Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriersA new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...- Sleeping over 8 hours daily? Senior Neurologist at Apollo Hospitals explains its underlying health issues and potential risksAre you sleeping more than 8 hours? New research has revealed that a study of nearly 500,000 people found a 'sweet spot' of 6.4 to 7.8 hour...
- AI-Powered drug discovery could transform treatment development for Alzheimer’s, Parkinson’s and other brain disorders.Researchers are increasingly using AI to accelerate the search for treatments for neurological conditions such as Alzheimer’s, Parkinson’s,...
- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
- Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vialEli Lilly is making Alzheimer's a major focus for its future innovations. The company is also expanding its specialty medicine offerings in...
- Alzheimer's a key part of Eli Lilly's India specialty medicine push, says company's country head Winselow TuckerEli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, a significant...
- The surprising danger of covering leftovers with aluminum foilA common kitchen habit of using aluminum foil for leftovers may be a hidden danger. The foil does not create an airtight seal, allowing bac...
- Novo Nordisk says Alzheimer's drug trial fails to meet main goalNovo Nordisk's Alzheimer's drug trials have ended without success. The semaglutide pill did not slow the brain disease's progression. This ...
- Novo Nordisk Stock Share Price Today: Why company's shares are down? Here's Alzheimer drug’s trial outcome, stock market impact, analysts insightsNovo Nordisk stock share price today fell after the company announced that semaglutide, used in Ozempic and Wegovy, failed to slow Alzheime...
- Eli Lilly get nod from CDSCO for it Alzheimer’s drug DonanemabEli Lilly has secured marketing authorization from India's CDSCO for its Alzheimer's drug, donanemab. This new disease-modifying therapy ta...
- Alzheimer's treatment? New drug found to slow down ‘clinical decline’ of disorder; Know about the medicine, its impact, how it works and moreThe new Alzheimer’s drug, Donanemab has demonstrated the ability to decelerate "clinical decline" by as much as 35%, enabling individuals w...
- Here's a long-awaited new FDA-Approved treatment for Alzheimer's - Read moreThis could mark a new era for Alzheimer's treatment as the FDA grants full approval to a promising new drug called 'Lecanemab.' The drug is...
- What causes Alzheimer's disease is still not known, but 'amyloid cascade hypothesis' may explain it betterProposed 30 years ago, the hypothesis described a series of events that culminates in Alzheimer's disease.
- Roche's Alzheimer's drug fails to meet goal in long awaited trialRoche's Alzheimer's drug candidate could not be shown to markedly slow dementia progression in two drug trials, leaving rivals Biogen and E...
- Biogen appoints ex-Sinofi boss Christopher Viehbacher as its next CEO. Here are the detailsAfter a month gap in choosing the new CEO after Michel Vounatsos, Biogen has finally named Christopher Viehbacher as its new CEO.
- Lecanemab: All about the Alzheimer's drug that shows promiseClinical trials on 1800 patients with early-stage Alzheimer's has showed that Lecanemab slows the advance of the disease.
- Japanese drugmaker Eisai comes up with new drug Lecanemab for treating Alzheimer's disease. See if it is effective?There is a new drug, which can probably help in treating Alzheimer's disease, but the authorities are yet to approve it, even though clinic...
- New Alzheimer's drug shows anti-ageing effectAlzheimer's disease is a progressive brain disorder and the most common cause of dementia in older adults.
- Novartis to test Alzheimer's drugs in patients without symptomsIn collaboration with the Banner Alzheimer's Institute, the Swiss company will study two therapies in cognitively healthy people who are at...
- Indian researcher bags Alzheimer's drug discovery award"I feel very proud that I have proved world class research in the area of medicine can be done in India,"
Load More
